Skip to main content

Advertisement

Log in

Significance of Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin in Patients with Hepatocellular Carcinoma Undergoing Hepatectomy

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) are well-known tumor markers of hepatocellular carcinoma (HCC). The aims of this study are to calculate the sensitivity/specificity of AFP and DCP measurement for the diagnosis of HCC, measure response rates of the markers following curative-intent resections, determine the correlations between the marker levels and clinicopathological prognostic variables, and determine the correlations between the marker levels before hepatectomy and those at diagnosis of recurrence.

Methods

A retrospective cohort study of 714 consecutive patients with HCC undergoing hepatectomy was carried out.

Results

The areas under the receiver operating characteristic curves were 0.79 versus 0.91 for AFP and DCP, respectively (P < 0.001). Positive AFP and DCP status became negative at 6 months post surgery in 184/229 (80.3%) and 245/246 (99.6%) patients, respectively (cutoff values being 20 ng/ml for AFP and 40 mAU/ml for DCP; P < 0.0001). No correlation was found between marker levels (rs = 0.23). The level of DCP, but not that of AFP, showed a close correlation with tumor size (rs = 0.51 and 0.19, respectively). They were associated with indices of tumor invasiveness without showing any specific associations. AFP and DCP levels in patients showing recurrence in ≤6 months correlated with the levels measured before surgery (rs = 0.78 and 0.49, respectively) but not in those showing recurrence after 2 years (rs = 0.31 and 0.30, respectively).

Conclusions

DCP is a more accurate, albeit complementary, HCC marker than AFP. While the levels of both markers increased with advancing tumor growth, no specific associations were found. The marker values at recurrence indicated the type of recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.

    Article  PubMed  Google Scholar 

  2. Abelev GI, Perova SD, Khramkova NI, et al. Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation. 1963;1:174–80.

    Article  CAS  PubMed  Google Scholar 

  3. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273–8.

    Article  CAS  PubMed  Google Scholar 

  4. Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61–6.

    Article  CAS  PubMed  Google Scholar 

  5. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.

    Article  CAS  PubMed  Google Scholar 

  6. Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Eng J Med. 1984;310:1427–31.

    CAS  Google Scholar 

  7. Tanabe Y, Ohnishi K, Nomura F, et al. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma. Am J Gastroenterol. 1988;83:1386–9.

    CAS  PubMed  Google Scholar 

  8. Fujiyama S, Izuno K, Gohshi K, et al. Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci. 1991;36:1787–92.

    Article  CAS  PubMed  Google Scholar 

  9. Grazi GL, Mazziotti A, Legnani C, et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg. 1995;1:249–55.

    Article  CAS  PubMed  Google Scholar 

  10. Nomura F, Ishijima M, Kuwa K, et al. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol. 1999;94:650–4.

    Article  CAS  PubMed  Google Scholar 

  11. Tsai SL, Huang GT, Yang PM, et al. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology. 1990;11:481–8.

    Article  CAS  PubMed  Google Scholar 

  12. Deyashiki Y, Nishioka Y, Takahashi K, et al. Evaluation of des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma. Cancer. 1989;64:2546–51.

    Article  CAS  PubMed  Google Scholar 

  13. Kasahara A, Hayashi N, Fusamoto H, et al. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci. 1993;38:2170–6.

    Article  CAS  PubMed  Google Scholar 

  14. Inoue S, Nakao A, Harada A, et al. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. Am J Gastroenterol. 1994;89:2222–6.

    CAS  PubMed  Google Scholar 

  15. Lamerz R, Runge M, Stieber P, et al. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Anticancer Res. 1999;19:2489–93.

    CAS  PubMed  Google Scholar 

  16. Cui R, He J, Zhang F, et al. Diagnostic value of protein induced by vitamin K absence (PIVKA-II) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer. 2003;88:1878–82.

    Article  CAS  PubMed  Google Scholar 

  17. Wang CS, Lin CL, Lee HC, et al. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol. 2005;11:6115–9.

    CAS  PubMed  Google Scholar 

  18. Mita Y, Aoyagi Y, Yanagi M, et al. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer. 1998;82:1643–8.

    Article  CAS  PubMed  Google Scholar 

  19. Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma varies according to tumor size. Am J Gastroenterol. 2006;101:2038–43.

    Article  CAS  PubMed  Google Scholar 

  20. Marrero JA, Su GL, Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37:1114–21.

    Article  CAS  PubMed  Google Scholar 

  21. Suehiro T, Sugimachi K, Matsumata T, et al. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer. 1994;73:2464–71.

    Article  CAS  PubMed  Google Scholar 

  22. Carr BI, Kanke F, Wise M, et al. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci. 2007;52:776–82.

    Article  CAS  PubMed  Google Scholar 

  23. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5:145–59.

    Article  CAS  PubMed  Google Scholar 

  24. Imamura H, Matsuyama Y, Miyagawa Y, et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg. 1999;86:1032–8.

    Article  CAS  PubMed  Google Scholar 

  25. Hagiwara S, Kudo M, Kawasaki T, et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41:1214–9.

    Article  PubMed  Google Scholar 

  26. Okuda H, Nakanishi T, Takatsu K, et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer. 2000;88:544–9.

    Article  CAS  PubMed  Google Scholar 

  27. Oishi K, Itamoto T, Amano H, et al. Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J Surg Oncol. 2007;95:311–6.

    Article  PubMed  Google Scholar 

  28. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rate of hepatocellular carcinoma: a randomized trial. Lancet. 2000;356:802–7.

    Article  CAS  PubMed  Google Scholar 

  29. Tateishi R, Yoshida H, Matsuyama Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int. 2008;2:17–30.

    Article  PubMed  Google Scholar 

  30. Liver Cancer Study Group in Japan. The general rules for the clinical and pathological study of primary liver cancer, 4th ed. Tokyo: Kanehara;2000.

    Google Scholar 

  31. Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1998;8:283–98.

    Article  Google Scholar 

  32. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054–61.

    Article  CAS  PubMed  Google Scholar 

  33. Nakao A, Suzuki Y, Issiki K, et al. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases. Am J Gastroenterol. 1991;86:62–6.

    CAS  PubMed  Google Scholar 

  34. Lefrere JJ, Gozin D, Lerable J, et al. Des-gamma-carboxyprothrombin assay in alcoholic cirrhotic patients with alpha-fetoprotein level slightly increased. Hepatology. 1986;6:1066–7.

    Article  CAS  PubMed  Google Scholar 

  35. Ohhira M, Ohtake T, Saito H, et al. Increase of serum des-gamma-carboxy prothrombin in alcoholic liver disease without hepatocellular carcinoma. Alcohol Clin Exp Res. 1999;23:67S–70S.

    Article  CAS  PubMed  Google Scholar 

  36. Nakagawa T, Seki T, Shiro T, et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol. 1999;14:281–6.

    CAS  PubMed  Google Scholar 

  37. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.

    Article  PubMed  Google Scholar 

  38. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported by Grant-in-Aid for Scientific Research (B) (20390352).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hiroshi Imamura MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamamoto, K., Imamura, H., Matsuyama, Y. et al. Significance of Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin in Patients with Hepatocellular Carcinoma Undergoing Hepatectomy. Ann Surg Oncol 16, 2795–2804 (2009). https://doi.org/10.1245/s10434-009-0618-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0618-y

Keywords

Navigation